Biotech entity
pharma is the sole category represented across all 1 tracked stories. RhodoLED is most often covered alongside Ameluz, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline.
Last mentioned: Mar 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. RhodoLED is most often covered alongside Ameluz, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. The 5 average consequence score is below the beat benchmark of 6 in the same window. RhodoLED appears in 1 tracked Biotech story from March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering RhodoLED. Shared-story counts are live from our verified record — not editorial picks.
Biofrontera Inc. (BFRI) has achieved record financial results for the fourth quarter and full year 2025, signaling a significant shift in the dermatology market toward photodynamic therapy. The company's performance reflects robust adoption of its flagship product, Ameluz, and its proprietary RhodoLED lamp technology in the United States.
RhodoLED is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
